Study identifier:D5100C00002
ClinicalTrials.gov identifier:NCT02780388
EudraCT identifier:2015-005318-30
CTIS identifier:N/A
A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects with Adult-onset Rheumatoid Arthritis
adult onset Rheumatoid arthritis
Phase 1
No
-
All
57
Interventional
18 Years - 70 Years
Allocation: Randomized
Endpoint Classification: Safety
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Apr 2019 by MedImmune, LLC
MedImmune, LLC
Study transferred to VelaBio
The purpose of this study is to determine whether MEDI4920 is safe and tolerable in patients with adult-onset rheumatoid arthritis.
Location
Location
Duncansville, PA, United States, 16635
Location
Miami Lakes, FL, United States, 33014
Location
Anniston, AL, United States, 36207
Location
Mesquite, TX, United States, 75150
Location
South Miami, FL, United States, 33143
Location
Debary, FL, United States, 32713
Location
Cincinnati, OH, United States, 45242
Location
Bialystok, Poland, 15-897
Arms | Assigned Interventions |
---|---|
Experimental: Cohort 1 Medi4920 (CD40L antagonist) | Biological/Vaccine: MEDI4920 MEDI4920 CD40L |
Placebo Comparator: Placebo Saline | Other: Placebo 0.9% saline for injection |
Experimental: Cohort 2 Medi4920 (CD40L antagonist) | Biological/Vaccine: MEDI4920 MEDI4920 CD40L |
Experimental: Cohort 3 Medi4920 (CD40L antagonist) | Biological/Vaccine: MEDI4920 MEDI4920 CD40L |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.